Selected international publications of the last years. The founders and team members of immatics are shown in bold letters.

The following list shows literature in chronological order selected from over 300 publications in international scientific journals.

Wallny HJ, Rammensee HG. 1990. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275-278.

Schild H, Rötzschke O, Kalbacher H, Rammensee HG. 1990. Limit of T celltolerance to self proteins by peptide presentation. Science 247:1587-1589.

Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254.

Rötzschke O, Falk K, Wallny HJ, Faath S, Rammensee HG. 1990. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249:283-287.

Falk K, Rötzschke O, Rammensee HG. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251.
 

Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732-736.
 

Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanovic S. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
 

Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. 1999.
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumorantigen for broadly applicable vaccine therapies. Blood 93:4309-4317.
 

Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. 2000.
Induction of CTL responses in vivo after vaccinations with peptide pulsed dendritic cells. Blood 96:3102-8.

Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30:2216-2225.

Gouttefangeas C, Rammensee HG. 2000. Problem solving for tumor immunotherapy. Nat Biotechnol. 18:491-492.

Schild H, Rammensee HG. 2000. Perfect use of imperfection. Nature. 404:709-710

Nussbaum AK, Kuttler C, Hadeler KP, Rammensee HG, Schild H. PAProC: aprediction algorithm for proteasomal cleavages available on the WWW. 2001. Immunogenetics 53:87-94.
 

Brossart P, Schneider A, Dill P, Schammann T, Grünebach F, Wirths S, Kanz L, Bühring HJ, Brugger W. 2001. The epithelial mucin MUC-1 is expressed in hematological malignancies and is recognized by MUC1 specific cytotoxic T-lymphocytes. Cancer Res. 61: 6846-50.

Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. 2002. Toward patient-specific tumor antigen selection for vaccination. Immunol. Rev.188:164-76

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, KurekR, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62:5818-27.

Schmidt SM, Schag K, Mueller MR, Weck MM, Appel S, Kanz L, Gruenebach F, Brossart P. 2003. Survivin is a shared tumor associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T-cells. Blood 102:571-6.

Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring HJ, Rammensee HG, Stevanovic S. 2003. Cutting edge: predetermined avidity of human CD8 Tcells expanded on calibrated MHC/anti-CD28-coated microspheres. J Immunol171:4974-8.

Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, Stevanovic S, Rammensee HG, Gouttefangeas C. 2004. CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother 54:750-8.

Lemmel C, Weik S, Eberle U, Dengjel J, Kratt T, Becker HD, Rammensee HG, Stevanovic S. 2004. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat Biotechnol 22:450-4.

Schag K, Schmidt SM, Muller MR, Weinschenk T, Appel S, Weck MM, Grunebach F, Stevanovic S, Rammensee HG, Brossart P. 2004. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 10:3658-66.

Schmidt SM, Schag K, Muller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grunebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P. 2004. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 64:1164-70.

Singh-Jasuja H, Emmerich NP, Rammensee HG. 2004. The Tubingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy. CancerImmunol Immunother 53:187-95.

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S. 2005. Autophagypromotes MHC class II presentation of peptides from intracellular sourceproteins. Proc Natl Acad Sci U S A 102:7779-80.

Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. 2005. Eur J Immunol 34:3644-51.

Wierecky J, Mueller M, Brossart P. 2006. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55:63-7.

Schmid DG, von der Mulbe FD, Fleckenstein B, Weinschenk T, Jung G. 2001. Broadband detection electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry to reveal enzymatically and chemically induced deamidation reactions within peptides. Anal Chem. 73:6008-13.

Schirle M, Weinschenk T, Stevanovic S. 2001. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Methods. 257:1-16. 

Lang KS, Moris A, Gouttefangeas C, Walter S, Teichgraber V, Miller M, Wernet D, Hamprecht K, Rammensee HG, Stevanovic S. High frequency of human cytomegalovirus (HCMV)-specific CD8+ T cells detected in a healthy CMV-seropositive donor. Cell Mol Life Sci. 2002 Jun;59(6):1076-80.

Schoor O, Weinschenk T, Hennenlotter J, Corvin S, Stenzl A, Rammensee HG, Stevanovic S. 2003. Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques. 35:1192-6, 1198-201.

Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Guckel B. 2003. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol. 129:397-409.

Seifert U, Maranon C, Shmueli A, Desoutter JF, Wesoloski L, Janek K,
Henklein P, Diescher S, Andrieu M, de la Salle H, Weinschenk T, Schild H,
Laderach D, Galy A, Haas G, Kloetzel PM, Reiss Y, Hosmalin A. 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol. 4:375-9.

Ouyang Q, Wagner WM, Walter S, Muller CA, Wikby A, Aubert G, Klatt T, Stevanovic S, Dodi T, Pawelec G. An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev. 2003 Apr;124(4):477-85.

Ouyang Q, Wagner WM, Wikby A, Walter S, Aubert G, Dodi AI, Travers P, Pawelec G. Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol. 2003 Jul;23(4):247-57.

Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S, Muller CA, Pircher H, Pawelec G. Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol. 2003 Aug;38(8):911-20.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovic S, Wallwiener D, Guckel B. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res. 2003 Oct 1;9(12):4376-86. 

Kramer BF, Schoor O, Kruger T, Reichle C, Muller M, Weinschenk T,
Hennenlotter J, Stenzl A, Rammensee HG, Stevanovic S. 2005. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther. 4:943-8.

Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, Weinschenk T, Muller M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanovic S. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother. 54:826-36.

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, Kreymborg K,
Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S. 2005. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A. 102:7922-7.

Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, Kloetzel PM,
Rammensee HG, Schild H, Holzhutter HG. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 62:1025-37.

Nastke MD, Herrgen L, Walter S, Wernet D, Rammensee HG, Stevanovic S. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci. 2005 Jan;62(1):77-86.

Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R, Xie W, Rammensee HG, Muller I, Buhring HJ, Niethammer D. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood. 2005 Jul 1;106(1):144-9. Epub 2005 Feb 24.

Carralot JP, Dumrese C, Wessel R, Riessen R, Autenrieth I, Walter S, Schoor O, Stevanovic S, Rammensee HG, Pascolo S. CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int Immunol. 2005 May;17(5):591-7. Epub 2005 Mar 31.

Teufel R, Carralot JP, Scheel B, Probst J, Walter S, Jung G, Hoerr I, Rammensee HG, Pascolo S. Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro. Cell Mol Life Sci. 2005 Aug;62(15):1755-62.

Walter S, Bioley G, Buhring HJ, Koch S, Wernet D, Zippelius A, Pawelec G, Romero P, Stevanovic S, Rammensee HG, Gouttefangeas C. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol. 2005 Oct;35(10):2876-85.
 

Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanovic S. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 12:4163-70.
 

Britten CM, Gouttefangeas C, Welters MJP, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Kollgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Woelfel T, van der Burg SH. 2007. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother.